Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

The "Usher Syndrome - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A comprehensive insight into the Usher Syndrome pipeline landscape highlights promising ...

STOCKHOLM--Sweden's central bank cut its key interest rate for the third time this year and said borrowing costs will likely be lowered again soon as a faltering economy threatens to push inflation ...